

## References

**Agency for Healthcare Research and Quality (AHRQ) (2011):**

Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease. AHRQ: Agency for Healthcare Research and Quality.

**Alderman EL, Kip KE, Whitlow PL, et al. (2004):** Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). *J Am Coll Cardiol*; 44(4):766-74.

**Alsheikh-Ali AA, Lin JL, Abourjaily P, et al. (2007):** Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. *Am J Cardiol*; 100:1499–501.

**Anderson JW, Gustafson NJ (2007):** High-carbohydrate, high-fiber diet. Is it practical and effective in treating hyperlipidemia. *Postgrad Med*; 82(4):40–355.

**Andr ws R, Berger JS, Brown DL. (2005):** Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. *JAMA*; 293 (21): 2641–7.

---

## ***References***

---

- Atkins D, Garber AM (2006):** When experts disagree: the cholesterol standoff. *Patient Care*; 30(20):62–91.
- Austin MA, McKnight B, Edwards K, et al. (2000):** Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study. *Circulation* 2000; 101: 2777–82.
- Awtry EH and Loscalzo J (2004):** Coronary Heart Disease. *Cecil Essentials of Medicine* (6 ed.). Philadelphia, PA: Saunders; 87–108.
- Baber U, Mehran R, Sharma SK, et al. (2011):** Impact of the everolimus-eluting stent on stent thrombosis a meta-analysis of 13 randomized trials. *J Am Coll Cardiol*; 58(15):1569-77.
- Baim DS, Grossman W (2006):** cardiac catheterization, angiography, and intervention, 7 th ed.pheladelphia: Lippincott Williams & Wilkins, 187-221
- Baim DS, Wahr D, George B, et al. (2002):** Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation*; 105(11):1285-90.
- Barter, Antonio M, LaRosa, et al. (2007):** "HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events". *New England Journal of Medicine* 357 (13): 1301–10.
-

## *References*

---

- Blake GH, Triplett LC (2005):** Management of hypercholesterolemia. *Am Fam Physician*; 51:1157–66.
- Bostorn AG, Cupples LA, Jenner JL, et al. (2006):** Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. *JAMA*; 276:544–8.
- Breckenridge WC (2010):** The role of lipoproteins and apolipoproteins in prediction of coronary heart disease risk. *Clin Invest Med*; 13:196–201.
- Brodie BR, Gersh BJ, Stuckey T, et al. (2010):** When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. *J Am Coll Cardiol*; 56(5):407-13.
- Brown BG, Stukovsky KH, Zhao XQ (2006):** Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. *Curr Opin Lipidol*; 17:631–6.
-

## ***References***

---

- Buchwald H, Varco RL, Matts JP, et al. (2010):** Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH). *N Engl J Med*; 323:946–55.
- Burillo E, Andres EM, Mateo-Gallego R, et al. (2010):** High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. *Heart*; 96:1345–51.
- Campbell CL, Smyth S, Montalescot G, et al. (2007):** Aspirin dose for the prevention of cardiovascular disease: a systematic review. *JAMA*; 297 (18): 2018–24.
- Carlson LA, Rosenhamer G (2008):** Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. *Acta Med Scand*; 223:405–18.
- Cavusoglu E, Kini AS, Marmur JD, et al. (2004):** Current status of rotational atherectomy. *Catheter Cardiovasc Interv*; 62(4): 485-98.
- Cohen DJ, Van Hout B, Serruys PW, et al. (2011):** Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. *N Engl J Med*; 364(11): 1016-26.
-

## ***References***

---

**Cohen JD, Pearson TA, Weart CW (2006):** Who really needs cholesterol-lowering drugs? *Patient Care*; 30(2):92–107.

**Culling KS, Neil HA, Gilbert M, et al. (2007):** Effects of short-term low- and high-carbohydrate diets on postprandial metabolism in non-diabetic and diabetic subjects. *Nutr Metab Cardiovasc Dis*; 19 (5): 345–51.

**Davidson MH, Testolin LM, Maki KC, et al. (2007):** A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in post-menopausal women. *Arch Intern Med*. 2007;157:1186–92.

**De Vita M, Burzotta F, Porto I, et al. (2010):** Thrombus aspiration in ST elevation myocardial infarction: comparative efficacy in patients treated early and late after onset of symptoms. *Heart*; 96(16): 1287-90.

**Dean, F. (2006):** Statistical methods in scientific researches. *European Journal of Scientific Research*; 14(3).

**Drexel, H. (2006):** "Reducing risk by raising HDL-cholesterol: the evidence". *European Heart Journal Supplements* 8: F23.

**Erkkilä AT, Booth SL (2008):** Vitamin K intake and atherosclerosis. *Curr. Opin. Lipidol.*; 19 (1): 39–42.

---

## ***References***

---

**Erratum, N. (2001):** The Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502[, N Engl J Med 2001; 345: 1506, 1716].

**Farrall M, Green FR, Peden JF, et al. (2006):** Genome-Wide Mapping of Susceptibility to Coronary Artery Disease Identifies a Novel Replicated Locus on Chromosome 17. PLoS Genetics; 2 (5): e72.

**Flier JS, Flier EM. (2007):** What fuels fat? Sci Amer 2007; 297: 72-81.

**Fogoros, Richard N. (2009):** "Raising Your HDL Levels". About.com. Retrieved 8 October 2009.

**Ford ES, Giles WH, Dietz WH (2002):** Prevalence of the metabolic syndrome among US adults: Findings from the third national health and nutrition examination survey. JAMA 2002; 287: 356–9.

**Fox KA, Poole-Wilson P, Clayton TC, et al. (2005):** 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet; 366(9489): 914-20.

**Fredrickson DS, Lees RS (1965):** A system for phenotyping hyperlipoproteinemia. Circulation; 31:321-327.

---

## ***References***

---

**Fredrickson DS, Levy RI, Lees RS (1967):** Fat transport in lipoproteins: An integrated approach to mechanisms and disorders. *N Engl J Med*; 276: 34-281.

**Ghatrehsamani K, Darabi M, Rahbani M, et al. (2009):** Combined hepatic lipase -514C/T and cholesteryl ester transfer protein I405V polymorphisms are associated with the risk of coronary artery disease. *Genet Test Mol Biomarkers*; 13 (6): 809–15.

**Ghazzal ZB, Dhawan SS, Sheikh A, et al. (2009):** Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. *Am J Cardiol*; 103:902–6.

**Gibbons RJ, Balady GJ, Beasley JW, et al. (1997):** ACC/AHA guidelines for exercise testing: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). *Circulation* 1997;96:345.

**Gotto AM Jr (2002):** Management of lipid and liprotein disorders. In: Gotto AM Jr, Pownall HJ, eds. *Manual of lipid disorders*. Baltimore: Williams and Wilkins.

**Gotto AM Jr (2006):** Lipid-regulating and antiatherosclerotic therapy: current options and future approaches. *Cleve Clin J Med*; 63:31–41.

---

## ***References***

---

- Grodstein F, Stampfer MJ, Colditz GA, et al. (1997):** Postmenopausal hormone therapy and mortality. *N Engl J Med*; 336:1769–75.
- Grundy SM, Vega GL (2007):** Fibrates: effects on lipids and lipoprotein metabolism. *Am J Med*; 93:9–20.
- Hannan EL, Racz MJ, Walford G, et al. (2005):** Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med*; 352(21): 2174-83.
- Harris WS. (2004):** Fish oil supplementation: evidence for health benefits. *Cleve Clin J Med* 2004; 71: 208–21
- Herrin J, Miller LE, Turkmani DF, et al. (2011):** National performance on door-in to door-out time among patients transferred for primary percutaneous coronary intervention. *Arch Intern Med*; 171(21): 1879-86.
- Hirano, Tsutomu; Nohtomi, Kyoko; Koba, Shinji; Muroi, Ayako; Ito, Yasuki, et al. (2008)** A simple and precise method for measuring HDL-cholesterol subfractions by a single precipitation followed by homogenous HDL-cholesterol assay". *The Journal of Lipid Research* 49 (5): 1130–6.doi:10.1194/jlr.D700027JLR200.PMID18223297.
-



## ***References***

---

**Hirsch EM, Anbe DT, Armstrong PW, et al. (2004):** ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol; 44(3): E1-E211.

**Hlatky MA, Boothroyd DB, Bravata DM, et al. (2009):** Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet; 373(9670):1190-7.

**Hooper L, Thompson RL, Harrison RA, et al. (2006):** Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ; 332 (7544): 752–60.

**Hueb W, Soares PR, Gersh BJ, et al. (2004):** The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol; 43(10): 1743-51.

**Jafri H, Alsheikh-Ali AA, Karas RH (2010):** Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern; 153:800–8.

---

## ***References***

---

- Jungnickel PW, Maloley PA, Vander Tuin EL, et al. (2007):** Effect of two aspirin pre-treatment regimens on niacin-induced cutaneous reactions. *J Gen Intern Med*; 12:591–6.
- Kaltoft A, Kelbaek H, Kløvgaard L, et al. (2010):** Increased rate of stent thrombosis and target lesion revascularization after filter protection in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: 15-month follow-up of the DEDICATION (Drug Elution and Distal Protection in ST Elevation Myocardial Infarction) trial. *J Am Coll Cardiol*; 55(9):867-71.
- Kaski JC (2004):** Pathophysiology and management of patients with chest pain and normal coronary arteriograms (cardiac syndrome X). *Circulation*; 109 (5): 568–72.
- Keller C (2001):** LDL-apheresis: results of longterm treatment and vascular outcome. *Atherosclerosis*; 86:1–8.
- Keller T, Squizzato A, Middeldorp S (2007):** Squizzato, Alessandro. ed. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. *Cochrane database of systematic reviews* (Online) (3): CD005158.
- Kwiterovich Jr and PO (2000):** "The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review". *The American journal of cardiology* **86** (12A): 5L–10L. doi:10.1016/s0002-9149(00)01461-2. PMID 11374859.
-

## ***References***

---

**Lanza GA (2007):** Cardiac syndrome X: a critical overview and future perspectives. *Heart*; 93 (2): 159–66.

**Levine GN, Bates ER, Blankenship JC, et al. (2011):** ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. *Circulation*.

**Levine GN, Keaney JF Jr, Vita JA (2005):** Cholesterol reduction in cardiovascular disease. *N Engl J Med*; 332:512–21.

**Locker PK, Jungbluth GL, Francom SF, et al. (2005):** Lofibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lofibrol Study Group. *Clin Pharm Ther*; 57:73–88.

**Lopez-Garcia E, Schulze MB, Meigs JB, et al. (2005):** Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. *J Nutr*; 135 (3): 562–6.

**Marwick TH. (1992):** Current status of non-invasive techniques for the diagnosis of myocardial ischemia. *Acta Clin Belg* 1992;47:1–5.

---

## ***References***

---

- McFadden EP, Stabile E, Regar E, et al. (2004)** Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. *Lancet* 2004; 364: 1519–21.
- Mega JL, Simon T, Collet JP, et al. (2010):** Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. *JAMA*; 304(16): 1821-30.
- Mineo C, Deguchi H, Griffin JH, et al. (2006):** Endothelial and antithrombotic actions of HDL. *Circ Res*; 98: 1352–64.
- Morrow DA, Wiviott SD, White HD, et al. (2009):** Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction. *Circulation*; 119(21): 2758-64.
- Mosca L, Banka CL, Benjamin EJ (2007):** Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. *Circulation*; 115 (11): 1481–501.
- Mozaffarian D, Katan MB, Ascherio A, et al. (2006):** Trans fatty acids and cardiovascular disease. *N. Engl. J. Med.*; 354 (15): 1601–13.
-

## ***References***

---

**National Cholesterol Education Program (1993):** Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II). Bethesda, Md: National Cholesterol Education Program, National Institutes of Health, National Heart, Lung, and Blood Institute. DHSS publication no. (NIH); 93-3095:5.

**National Cholesterol Education Program (1997):** Cholesterol lowering in the patient with coronary heart disease. Bethesda, Md.: National Institutes of Health, National Heart, Lung, and Blood Institute. DHHS publication no. (NIH); 97-3794.

**National Cholesterol Education Program (2001):** Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the NCEP. *Circulation*, 106 (2002) 3143–21.

**National Institute of Health (2011):** NIH stops clinical trial on combination cholesterol treatment. National Heart, Lung, and Blood Institute (NHLBI). Retrieved 2 June 2011.

**Nicholls SJ, Tuzcu EM, Sipahi I, et al. (2007):** Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. *JAMA*; 297:499–508.

---

## ***References***

---

- Oikawa S, Yokoyama M, Origasa H. et al. (2009):** Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study. *Atherosclerosis*; 206 (2): 535–9.
- Olsson AG, Schwartz GG, Szarek M, et al. (2005):** High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. *Eur Heart J*;26:890–6.
- Padmanaban P, Toora BD (2011):** Hemoglobin: Emerging marker in stable coronary artery disease. *Chron Young Sci*; 2:109-10.
- Pedersen TR, Kjekshus J, Berg K, et al. (2006):** Cholesterol lowering and the use of healthcare resources: results of the Scandanavian Simvastatin Survival Study. *Circulation*; 93: 1796–802.
- Pijls NH, Fearon WF, Tonino PA, et al. (2010):** Fractional flow reserve versus angiography for guiding PCI in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. *J Am Coll Cardiol*; 56(3):177-84.
-

## ***References***

---

- Pina IL, Balady GJ, Hanson P, et al. (1995):** Guidelines for clinical exercise testing laboratories: a statement for healthcare professionals from the committee on exercise and rehabilitation, American Heart Association. *Circulation* 1995;91:912.
- Piscione F, Piccolo R, Cassese S, et al. (2010):** Is direct stenting superior to stenting with predilation in patients treated with PCI ? Results from a meta-analysis of 24 randomised controlled trials. *Heart*; 96(8):588-94.
- Pocock SJ, Henderson RA, Rickards AF, et al. (1995):** Meta-analysis of randomised trials comparing coronary angioplasty with bypass surgery. *Lancet*; 346(8984):1184-9.
- Price MJ, Berger PB, Teirstein PS, et al. (2011):** Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA*; 305(11): 1097-105.
- Rao SV, Kaltenbach LA, Weintraub WS, et al. (2011):** Prevalence and outcomes of same-day discharge after elective percutaneous coronary intervention among older patients. *JAMA*; 306(13): 1461-7.
- Rathore SS, Curtis JP, Chen J, et al. (2009):** Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. *BMJ*; 338:b1807.
-

## ***References***

---

- Ridker P, Cook N, Lee I, et al. (2005):** A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. *N Engl J Med*; 352 (13): 1293–304.
- Rosamond W, Flegal K, Friday G (2007):** Heart disease and stroke statistics: Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation*; 115 (5): e69–171
- Ryan TJ, Baumann WB, Kennedy JW (1993):** Guidelines for percutaneous transluminal coronary angioplasty: a report of the AHA/ACC Task Force. *J Am Coll Cardiol* 1993; 22: 2033-2055
- Scanlon P, Faxon D, Audet A (1999):** ACC/AHA guidelines for coronary arteriography. *J Am Coll Cardiol* 33:1756.
- Schaefer EJ (2001):** Diagnosis and management of lipoprotein disorders. In: Rifkind BM, ed. *Drug treatment of hyperlipidemia*. New York: Dekker; 17–52.
- Seo SM, Choo EH, Koh YS, et al. (2011):** High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. *Heart* 2011, **97**: 1943-1950 doi:10.1136/hrt.2011.225466.
-



## ***References***

---

**Serruys PW, Lemos PA, van Hout BA (2004):** Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). *Heart*; 90(9):995-8.

**Serruys PW, Ong AT, van Herwerden LA, et al. (2005):** Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. *J Am Coll Cardiol*; 46(4):575-81.

**Smith DA (2004):** Hypercholesterolemia: putting the new expert panel guidelines to work for your patient. *Consultant*; 34:838–52.

**Smolders B, Lemmens R, Thijs V (2007):** Lipoprotein (a) and stroke: a meta-analysis of observational studies. *Stroke*; 38 (6): 1959–66.

**Snyder S (2010):** Comparison of cholesterol-lowering regimens. *Am Fam Physician*; 42:761–8.

**Stegmann, T.J. (2004):** New Vessels for the Heart. Angiogenesis as New Treatment for Coronary Heart Disease: The Story of its Discovery and Development. Henderson, Nevada 89012, USA.

**Stegmann, T.J. (2007):** Protein promise in heart disease. *GCPJ*; 21-24.

---

## ***References***

---

**Stone GW, Ellis SG, Colombo A, et al. (2007):** Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. *Circulation*; 115(22):2842-7.

**Stone GW, Kedhi E, Kereiakes DJ, et al. (2011):** Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. *Circulation*; 124(8): 893-900.

**Stone GW, Lansky AJ, Pocock SJ, et al. (2009):** Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. *N Engl J Med*; 360(19): 1946-59.

**Swarbrick MM, Stanhope KL, Elliott SS (2008):** Consumption of fructose-sweetened beverages for 10 weeks increases postprandial triacylglycerol and apolipoprotein-B concentrations in overweight and obese women. *Br. J. Nutr.*; 100 (5): 1–6.

**Taylor AJ, Villines TC, Stanek EJ, et al. (2009):** Extended-release niacin or ezetimibe and carotid intima-media thickness. *N Engl J Med*; 361:2113–22.

**The Second Randomized Intervention Treatment of Angina (RITA-2) Trial (1997):** Coronary angioplasty versus medical therapy for angina: RITA-2 trial participants. *Lancet*; 350(9076): 461-8.

---

## ***References***

---

- Toth and Peter (2005).** The "good cholesterol" High-Density Lipoprotein. *Circulation* **111** (5): e89-e91. Retrieved 2 June 2011.
- Vlaar PJ, Svilaas T, van der Horst IC, et al. (2008):** Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study. *Lancet*; 371(9628): 1915-20.
- Wang TD, Chen WJ, Chien KL, et al. (2001):** Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. *Am J Cardiol*; 88:737–43.
- Winchester DE, Wen X, Brearley WD, et al. (2011):** Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization A Meta-Analysis of Randomized Trials Performed in the Era of Stents and Thienopyridines. *J Am Coll Cardiol*; 57(10):1190-9.
- Wong EML, Wu EB, Chan WWM, Yu CM, et al. (2006)** A review of the management of patients after percutaneous coronary intervention. *International Journal of Clinical Practice* 2006;60:582-589).
-

## ***References***

---

- Yeshurun D, Gotto AM Jr (2005):** Hyperlipidemia: perspectives in diagnosis and treatment. *South Med J*; 88: 379–91.
- Yokoyama M, Origasa H, Matsuzaki M (2007):** Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. *Lancet*; 369 (9567): 1090–8.
- Zhao XQ, Krasuski RA, Baer J, et al. (2009):** Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). *Am J Cardiol*; 104:1457–64.
-